Cargando…
Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma
BACKGROUND: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). METHODS: This was a retrospective review of 154 pati...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199726/ https://www.ncbi.nlm.nih.gov/pubmed/25329593 http://dx.doi.org/10.1371/journal.pone.0110765 |
_version_ | 1782339964546056192 |
---|---|
author | Tao, Chang-Juan Lin, Li Zhou, Guan-Qun Tang, Ling-Long Chen, Lei Mao, Yan-Ping Zeng, Mu-Sheng Kang, Tie-Bang Jia, Wei-Hua Shao, Jian-Yong Mai, Hai-Qiang Lin, Ai-Hua Ma, Jun Sun, Ying |
author_facet | Tao, Chang-Juan Lin, Li Zhou, Guan-Qun Tang, Ling-Long Chen, Lei Mao, Yan-Ping Zeng, Mu-Sheng Kang, Tie-Bang Jia, Wei-Hua Shao, Jian-Yong Mai, Hai-Qiang Lin, Ai-Hua Ma, Jun Sun, Ying |
author_sort | Tao, Chang-Juan |
collection | PubMed |
description | BACKGROUND: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). METHODS: This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients (47.4%) received 5–7 weeks of 30–40 mg/m(2) cisplatin weekly; 81 patients (52.6%) received two or three cycles of 80 mg/m(2) cisplatin every three weeks. IMRT was delivered at 68 Gy/30 fractions to the nasopharyngeal gross target volume and 60–66 Gy to the involved neck area. RESULTS: The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months (range, 6–123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis–free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease. The incidence of acute toxicities was similar between groups. CONCLUSION: IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease. |
format | Online Article Text |
id | pubmed-4199726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41997262014-10-21 Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma Tao, Chang-Juan Lin, Li Zhou, Guan-Qun Tang, Ling-Long Chen, Lei Mao, Yan-Ping Zeng, Mu-Sheng Kang, Tie-Bang Jia, Wei-Hua Shao, Jian-Yong Mai, Hai-Qiang Lin, Ai-Hua Ma, Jun Sun, Ying PLoS One Research Article BACKGROUND: We aimed to compare the long-term survival outcomes and acute toxicity of cisplatin administered weekly versus every three weeks concurrently with intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). METHODS: This was a retrospective review of 154 patients with histologically proven, non-disseminated NPC who were treated using IMRT between January 2003 and December 2007. Seventy-three patients (47.4%) received 5–7 weeks of 30–40 mg/m(2) cisplatin weekly; 81 patients (52.6%) received two or three cycles of 80 mg/m(2) cisplatin every three weeks. IMRT was delivered at 68 Gy/30 fractions to the nasopharyngeal gross target volume and 60–66 Gy to the involved neck area. RESULTS: The clinical characteristics and treatment factors of the two groups were well-balanced. The median follow-up was 74 months (range, 6–123 months), and the 5-year overall survival, disease-free survival, locoregional relapse-free survival, and distant metastasis–free survival rates were 85.2% vs. 78.9% (P = 0.318), 71.6% vs. 71.0% (P = 0.847), 93.5% vs. 92.6% (P = 0.904), and 80.9% vs. 80.1% (P = 0.925) for the group treated every three weeks and weekly, respectively. Subgroup analyses indicated no significant differences in the survival rates of the two groups among patients with early- or advanced-stage disease. The incidence of acute toxicities was similar between groups. CONCLUSION: IMRT with concurrent cisplatin administered weekly or every three weeks leads to similar long-term survival outcomes and acute toxicity in NPC regardless of whether patients have early- or advanced-stage disease. Public Library of Science 2014-10-16 /pmc/articles/PMC4199726/ /pubmed/25329593 http://dx.doi.org/10.1371/journal.pone.0110765 Text en © 2014 Tao et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Tao, Chang-Juan Lin, Li Zhou, Guan-Qun Tang, Ling-Long Chen, Lei Mao, Yan-Ping Zeng, Mu-Sheng Kang, Tie-Bang Jia, Wei-Hua Shao, Jian-Yong Mai, Hai-Qiang Lin, Ai-Hua Ma, Jun Sun, Ying Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title | Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title_full | Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title_fullStr | Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title_full_unstemmed | Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title_short | Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma |
title_sort | comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4199726/ https://www.ncbi.nlm.nih.gov/pubmed/25329593 http://dx.doi.org/10.1371/journal.pone.0110765 |
work_keys_str_mv | AT taochangjuan comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT linli comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT zhouguanqun comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT tanglinglong comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT chenlei comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT maoyanping comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT zengmusheng comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT kangtiebang comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT jiaweihua comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT shaojianyong comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT maihaiqiang comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT linaihua comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT majun comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma AT sunying comparisonoflongtermsurvivalandtoxicityofcisplatindeliveredweeklyversuseverythreeweeksconcurrentlywithintensitymodulatedradiotherapyinnasopharyngealcarcinoma |